JP2008512484A5 - - Google Patents

Download PDF

Info

Publication number
JP2008512484A5
JP2008512484A5 JP2007531364A JP2007531364A JP2008512484A5 JP 2008512484 A5 JP2008512484 A5 JP 2008512484A5 JP 2007531364 A JP2007531364 A JP 2007531364A JP 2007531364 A JP2007531364 A JP 2007531364A JP 2008512484 A5 JP2008512484 A5 JP 2008512484A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
heart
phosphatase inhibitor
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007531364A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008512484A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/032162 external-priority patent/WO2006029319A2/en
Publication of JP2008512484A publication Critical patent/JP2008512484A/ja
Publication of JP2008512484A5 publication Critical patent/JP2008512484A5/ja
Pending legal-status Critical Current

Links

JP2007531364A 2004-09-09 2005-09-08 心臓細胞におけるホスファターゼ活性の調節 Pending JP2008512484A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60821404P 2004-09-09 2004-09-09
PCT/US2005/032162 WO2006029319A2 (en) 2004-09-09 2005-09-08 Modulating phosphatase activity in cardiac cells

Publications (2)

Publication Number Publication Date
JP2008512484A JP2008512484A (ja) 2008-04-24
JP2008512484A5 true JP2008512484A5 (enExample) 2008-10-23

Family

ID=36037020

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007531364A Pending JP2008512484A (ja) 2004-09-09 2005-09-08 心臓細胞におけるホスファターゼ活性の調節

Country Status (7)

Country Link
US (4) US9114148B2 (enExample)
EP (1) EP1791432A4 (enExample)
JP (1) JP2008512484A (enExample)
CN (1) CN101056539B (enExample)
AU (1) AU2005282352B2 (enExample)
CA (1) CA2579519A1 (enExample)
WO (1) WO2006029319A2 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7964196B2 (en) * 2004-05-25 2011-06-21 Chimeros, Inc. Self-assembling nanoparticle drug delivery system
JP2009525757A (ja) * 2006-02-10 2009-07-16 ザ ユニバーシティ オブ シンシナティ 心機能のレギュレータとしてのホスファターゼインヒビタープロテイン−１
JP2009533350A (ja) * 2006-04-07 2009-09-17 キメロス， インコーポレイテッド Ｂ細胞悪性疾患を処置するための組成物および方法
PL2044199T3 (pl) * 2006-07-25 2013-04-30 Celladon Corp Przedłużony, podawany z prądem krwi, nasierdziowy, wieńcowy wlew wektorów wirusowych na bazie wirusów towarzyszących adenowirusom, zawierający SERCA2a do terapii genowej
US20090226525A1 (en) * 2007-04-09 2009-09-10 Chimeros Inc. Self-assembling nanoparticle drug delivery system
US8455628B2 (en) * 2007-05-02 2013-06-04 Intrexon Corporation PP1 ligands
EP2396343B1 (en) 2009-02-11 2017-05-17 The University of North Carolina At Chapel Hill Modified virus vectors and methods of making and using the same
WO2010120874A2 (en) 2009-04-14 2010-10-21 Chimeros, Inc. Chimeric therapeutics, compositions, and methods for using same
JP5370969B2 (ja) * 2010-02-23 2013-12-18 国立大学法人金沢大学 心筋障害の検査方法
CA2826273C (en) 2011-02-10 2021-11-02 The University Of North Carolina At Chapel Hill Viral vectors with modified transduction profiles and methods of making and using the same
CA2847888A1 (en) 2011-09-09 2013-03-14 Biomed Realty, L.P. Methods and compositions for controlling assembly of viral proteins
ES2926774T3 (es) 2013-03-15 2022-10-28 Univ North Carolina Chapel Hill Métodos y composiciones para vectores AAV de doble unión de glicano
AU2016206624B2 (en) 2015-01-14 2020-08-06 The University Of North Carolina At Chapel Hill Methods and compositions for targeted gene transfer
JP6854766B2 (ja) 2015-01-26 2021-04-07 イエール ユニバーシティ チロシンキナーゼ阻害剤を用いる組成物および方法
WO2016134300A1 (en) 2015-02-20 2016-08-25 Board Of Regents, The University Of Texas System Methods and compositions for attenuated chlamydia as vaccine and vector
IL314171A (en) 2015-09-28 2024-09-01 Univ Florida Methods and compositions for antibody-evading virus vectors
WO2018035046A1 (en) 2016-08-15 2018-02-22 President And Fellows Of Harvard College Treating infections using idsd from proteus mirabilis
WO2018170310A1 (en) 2017-03-15 2018-09-20 The University Of North Carolina At Chapel Hill Polyploid adeno-associated virus vectors and methods of making and using the same
CA3092107A1 (en) 2018-02-28 2019-09-06 The University Of North Carolina At Chapel Hill Methods and compositions for antibody-evading virus vectors
CA3095179A1 (en) 2018-04-03 2019-10-10 Stridebio, Inc. Antibody-evading virus vectors
BR112020020266A2 (pt) 2018-04-03 2021-01-19 Stridebio, Inc. Vetores de vírus com evasão de anticorpos
MX2020010465A (es) 2018-04-03 2021-01-08 Vectores de virus para direccionamiento a tejidos oftalmicos.
CN113727992A (zh) 2019-03-21 2021-11-30 斯特里迪比奥公司 重组腺相关病毒载体
CN110367188A (zh) * 2019-04-04 2019-10-25 上海大学 心肌层转染慢病毒的小鼠模型的构建方法
AU2020263392A1 (en) 2019-04-26 2021-10-28 The University Of North Carolina At Chapel Hill Methods and compositions for dual glycan binding AAV2.5 vector
CN114787180A (zh) 2019-10-17 2022-07-22 斯特里迪比奥公司 用于治疗c型尼曼-匹克病的腺相关病毒载体
MX2022004353A (es) 2019-10-17 2022-07-19 Casete de transferencia de aav.
FI4103214T3 (fi) 2020-02-13 2026-07-03 Tenaya Therapeutics Inc Geeniterapian vektorit sydänsairauden hoitoon
CN116406297A (zh) * 2020-08-05 2023-07-07 阿斯克肋匹奥生物制药公司 治疗心脏疾患和充血性心力衰竭以及施用aav载体的方法
JP2023542614A (ja) 2020-08-19 2023-10-11 サレプタ セラピューティクス， インコーポレイテッド レット症候群の治療のためのアデノ随伴ウイルスベクター
CN116490514A (zh) 2020-10-28 2023-07-25 北卡罗来纳-查佩尔山大学 用于双重聚糖结合aav2.5载体的方法和组合物
TW202242124A (zh) 2021-01-14 2022-11-01 美商史崔德生物公司 靶向ｔ細胞之ａａｖ載體
JP2024515626A (ja) 2021-04-16 2024-04-10 アスクレピオス バイオファーマシューティカル， インコーポレイテッド 血液脳関門を横断し低減された液性応答を惹起する合理的ポリプロイドａａｖビリオン
TW202342759A (zh) 2022-02-04 2023-11-01 美商史崔德生物公司 重組腺相關病毒載體及其使用方法
WO2024124019A2 (en) 2022-12-07 2024-06-13 Ginkgo Bioworks, Inc. Aav vectors targeting hematopoietic stem cells
EP4722234A1 (en) * 2023-06-05 2026-04-08 BethphaGen Inc. Gene construct comprising nucleotides encoding decoy peptides for inhibiting protein phosphatase 1-mediated dephosphorylation of phospholamban and nucleotides encoding ccn5 protein or fragments thereof, and use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5589375A (en) * 1992-10-06 1996-12-31 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E. V. PTP 1D: a novel protein tyrosine phosphatase
US7745416B2 (en) * 1995-04-11 2010-06-29 The Regents Of The University Of California Method for in vivo regulation of cardiac muscle contractility
US20020040010A1 (en) * 1997-07-22 2002-04-04 Anthony Rosenzweig Use of agents to treat heart disorders
US20050095227A1 (en) * 1997-07-22 2005-05-05 The General Hospital Corporation Treating heart failure
US6416992B1 (en) * 1998-10-13 2002-07-09 Avigen, Inc. Compositions and methods for producing recombinant adeno-associated virus
WO2002055710A2 (en) * 2001-01-11 2002-07-18 Bayer Ag Regulation of human purple acid phosphatase
US20040214760A1 (en) * 2001-01-15 2004-10-28 Ramesh Gupta Inhibition pf protein-phosphatases for the treatment of heart failure
US20020159978A1 (en) * 2001-02-06 2002-10-31 James Allen Muscle-directed gene transfer by use of recombinant AAV-1 and AAV-6 virions
WO2005049850A2 (en) * 2003-11-14 2005-06-02 University Of Washington Compositions and methods for systemic nucleic acid sequence delivery
JP2009525757A (ja) 2006-02-10 2009-07-16 ザ ユニバーシティ オブ シンシナティ 心機能のレギュレータとしてのホスファターゼインヒビタープロテイン−１

Similar Documents

Publication Publication Date Title
Hulot et al. Gene therapy for the treatment of heart failure: promise postponed
Müller et al. Targeting the heart with gene therapy-optimized gene delivery methods
JP2020518268A5 (enExample)
JP2004533405A5 (enExample)
JP2007531564A (ja) 遺伝子発現を制御する埋め込み可能なシステム
JP2009525757A5 (enExample)
KR20230084542A (ko) 플라코필린 2 유전자 치료 방법 및 조성물
EP4069849B1 (en) Liver-specific promoter and application thereof
HK1222884A1 (zh) 用於治疗心力衰竭和增加心脏功能的不能产生环腺苷酸的腺苷酸环化酶和组合物和方法
EP1317289B1 (en) Dominant negative PLB mutant for use in treating cardiac disease
US20030072744A1 (en) Methods of altering cardiac cell phenotype
WO2015150914A2 (en) Systemic delivery of virus vectors encoding urocortin-2 and related genes to treat diabetes-related cardiac dysfunction and congestive heart failure
Xu et al. Optimizing drug delivery for enhancing therapeutic efficacy of recombinant human endostatin in cancer treatment
JP2019517262A5 (enExample)
ES2975422T3 (es) Proteínas con actividad cardioprotectora
JP2002533359A (ja) 組換えアデノ随伴ウイルスベクターを用いる、心筋細胞への効率的かつ安定なインビボでの遺伝子移入
CN1301181A (zh) 基因转移介导的血管生成疗法和血管内基因传递技术
JP2005505510A (ja) Ｖｅｇｆ−ｂによる血管新生の刺激
CN115885043A (zh) 用于dwarf开放阅读框的腺相关病毒载体
Avril et al. Defining the success of cardiac gene therapy: how can nuclear imaging contribute?
AU2007277392A1 (en) Extended antegrade epicardial coronary infusion of adeno-associated viral vectors for gene therapy
Ishikawa et al. Current methods in cardiac gene therapy: overview
Askari et al. Targeted gene therapy for the treatment of cardiac dysfunction
WO2018090042A1 (en) Methods of treating heart failure
Fargnoli et al. Gene therapy in heart failure